Selective blockade of receptor-mediated cyclic GMP formation in N1E-115 neuroblastoma cells by an inhibitor of nitric oxide synthesis.
McKinney
M
M
Department of Pharmacology, Mayo Clinic Jacksonville, FL 32224.
Bolden
C
C
Smith
C
C
Johnson
A
A
Richelson
E
E
D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001920:Bradykinin / Q000494:pharmacology; D002217:Carbachol / Q000494:pharmacology; D006152:Cyclic GMP / Q000096:biosynthesis*; D006632:Histamine / Q000494:pharmacology; D051379:Mice; D009447:Neuroblastoma / Q000378:metabolism*; D009496:Neurotensin / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism*; D010716:Phosphatidylinositols / Q000378:metabolism; D011955:Receptors, Drug / Q000502:physiology*; D014407:Tumor Cells, Cultured / Q000378:metabolism; D019323:omega-N-Methylarginine
D010716:Phosphatidylinositols; D011955:Receptors, Drug; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D009496:Neurotensin; D006632:Histamine; D002217:Carbachol; D001120:Arginine; D006152:Cyclic GMP; D001920:Bradykinin